Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 4

Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus

NCT00572559 · View on ClinicalTrials.gov ↗

Study Summary

Ventilator-associated pneumonia (VAP) is a commonplace complication of intensive care patients ventilated for longer than 48 hours. Methicillin-resistant Staphylococcus aureus (MRSA) is the cause of late onset VAP in up to about 30% of cases in US hospitals. Ineffective treatment of MRSA VAP clearly leads to prolonged mechanical ventilation and is probably associated with higher mortality. The purpose of this protocol is to directly compare linezolid and vancomycin specifically for MRSA VAP.

Interventions

  • DRUG Vancomycin
  • DRUG Linezolid

Study Locations (20)

California

  • Pfizer Investigational Site — Palm Springs
  • Pfizer Investigational Site — Rancho Mirage
  • Pfizer Investigational Site — Redlands
  • Pfizer Investigational Site — Sacramento
  • Pfizer Investigational Site — Sacramento

Georgia

  • Pfizer Investigational Site — Augusta
  • Pfizer Investigational Site — Decatur
  • Pfizer Investigational Site — North East Atlanta
  • Pfizer Investigational Site — North East Atlanta
  • Pfizer Investigational Site — North East Atlanta

Illinois

  • Pfizer Investigational Site — Chicago
  • Pfizer Investigational Site — Peoria
  • Pfizer Investigational Site — Peoria
  • Pfizer Investigational Site — Peoria

Connecticut

  • Pfizer Investigational Site — Norwalk
  • Pfizer Investigational Site — Waterbury
  • Pfizer Investigational Site — Waterbury

Arizona

  • Pfizer Investigational Site — Phoenix
  • Pfizer Investigational Site — Phoenix

Hawaii

  • Pfizer Investigational Site — ‘Ewa Beach

Trial Details

FieldValue
Enrollment Target 149 participants
Start Date 2002-11
Est. Completion 2005-01
Phase Phase 4

Sponsor

Pfizer

769 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00572559

The ClinicalTrials.gov registry entry for NCT00572559 describes a study currently listed as completed. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Pneumonia, Ventilator-Associated appearing as the primary indexed condition, and to 2 interventions — of which Vancomycin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00572559 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Georgia, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00572559 about?

NCT00572559 is a clinical study titled "Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus". Ventilator-associated pneumonia (VAP) is a commonplace complication of intensive care patients ventilated for longer than 48 hours. Methicillin-resistant Staphylococcus aureus (MRSA) is the cause of late onset VAP in up to about 30% of cases in US hospitals. Ineffective treatment of MRSA VAP clearly...

What is the current status of trial NCT00572559?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 149 participants. The study started on 2002-11. Estimated completion is 2005-01.

What conditions does trial NCT00572559 study?

This clinical trial studies the following conditions: Pneumonia, Ventilator-Associated. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00572559?

The interventions under investigation include: Vancomycin (DRUG), Linezolid (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00572559?

This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00572559 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial